CHRN ChronoScale Corp.

ChronoScale announced an expanded agreement with an existing customer and a new customer contract that, together with its current contracts and deployment schedule, are expected to support a $1 billion annualized revenue run rate by Q3 2027. The Menlo Park-based accelerated computing and AI infrastructure provider said the agreements include an extension with an existing AI infrastructure customer and a new customer deal. ChronoScale cautioned that achieving the contracted revenue depends on timely infrastructure deployment, power and equipment availability, and access to capital on acceptable terms. CEO Cenly Chen said the agreements, combined with existing contracts and the current deployment schedule, provide visibility toward a $1 billion annualized revenue run rate during 2027. The company also completed the sale of its Ekso Bionics business, allowing it to focus operations and capital allocation on accelerated computing and AI infrastructure. $CHRN

$CHRN This has low float and APLD ownes 96.5 % which could be holding this back. APLD needs to state publicly there are no current plans to sell the stock. In my opinion this will fly afterwards. APLD could say it during earnings call Oct 7.

$CHRN might take a month or so more of chopping around but watch for a powerful breakout from this symmetrical triangle formation. Northland Capital Markets just initiated the company at outperform with a $32 price target (46% upside) ⬆️ AI infrastructure / GPU compute company with nice potential.

$CHRN $APLD 🫡 Q: “Then a follow-up just on ChronoScale signed the 50 megawatts. Obviously, it seems like it could start ramping quite a bit from here. Just wondering kind of as we look out a few years, could we almost expect ChronoScale to be at 400 megawatts or so in Applied sites, almost like what CoreWeave did or less so?” Wes: “you’ll see over the coming month or so, the strategy we’re using to secure data center capacity for ChronoScale…” “A significant amount, actually, in 2027.”

$CHRN ChronoScale told the market Thursday evening it now has AI-infrastructure customer agreements that take contracted annualized run-rate revenue to $1.0B by calendar Q3 2027. Two agreements: an expansion with an existing customer and a brand-new one. It also closed the sale of the legacy Ekso Bionics unit on Sept 30. The tape's read: nothing. The stock closed Friday at 19.21, down a hair, after the company put a billion-dollar headline out. The release itself names the reasons for skepticism: timely deployment, availability of power and equipment, and access to capital on acceptable terms. The scale of the claim: Q2 revenue was 18.4 million. A $1.0B run-rate means about 13-14x that quarterly revenue, roughly a year out, with both counterparties unnamed. At 2.8 billion in market cap, the stock trades at ~2.8x that 2027 number. If the contracts were firm, you'd expect a move. The market priced it as an aspiration, not revenue.

$CHRN I just got 2 t bones from that crime candle from my father in law. Thanks guys. I was off by 40 mins but thanks anyways.

$CHRN: ChronoScale expanded one AI customer contract and added another, supporting $1 billion annualized run-rate revenue by Q3 2027.

$CHRN expands AI infrastructure agreements to drive $1 billion run-rate revenue by Q3 2027 and completes the Ekso Bionics sale.

$CHRN ChronoScale Holdings Corporation (CHRN) reported the following financial results for its most recent quarters:Fiscal Q4 2026 (Ended May 31, 2026 / Reported August 2026): $18.4 million in revenue with a loss of $0.12 per share.Fiscal Q3 2026 (Ended February 28, 2026): $18.09 million in revenue with a net loss of $12.65 million.

$CHRN ChronoScale Holdings (formerly operating under the symbol EKSO) has accumulated a total lifetime net loss of over $262 million since its inception as an exoskeleton developer.The company never achieved a single profitable year while trading as Ekso Bionics. Instead, it consistently generated net losses that ultimately forced its early 2026 merger and strategic pivot into the AI infrastructure space

$CHRN refinanced its term loan with a First Amendment extending maturity to Nov 12, 2026.